Cargando…

HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy

CD4(+) T cells differentiate into various T helper subsets characterized by distinct cytokine secreting profiles that confer them effector functions adapted to a variety of infectious or endogenous threats. Regulatory CD4(+) T cells are another specialized subset that plays a fundamental role in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Couture, Alexandre, Garnier, Anthony, Docagne, Fabian, Boyer, Olivier, Vivien, Denis, Le-Mauff, Brigitte, Latouche, Jean-Baptiste, Toutirais, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533590/
https://www.ncbi.nlm.nih.gov/pubmed/31156634
http://dx.doi.org/10.3389/fimmu.2019.01081
_version_ 1783421238935289856
author Couture, Alexandre
Garnier, Anthony
Docagne, Fabian
Boyer, Olivier
Vivien, Denis
Le-Mauff, Brigitte
Latouche, Jean-Baptiste
Toutirais, Olivier
author_facet Couture, Alexandre
Garnier, Anthony
Docagne, Fabian
Boyer, Olivier
Vivien, Denis
Le-Mauff, Brigitte
Latouche, Jean-Baptiste
Toutirais, Olivier
author_sort Couture, Alexandre
collection PubMed
description CD4(+) T cells differentiate into various T helper subsets characterized by distinct cytokine secreting profiles that confer them effector functions adapted to a variety of infectious or endogenous threats. Regulatory CD4(+) T cells are another specialized subset that plays a fundamental role in the maintenance of immune tolerance to self-antigens. Manipulating effector or regulatory CD4(+) T cells responses is a promising immunotherapy strategy for, respectively, chronical viral infections and cancer, or severe autoimmune diseases and transplantation. Adoptive cell therapy (ACT) is an emerging approach that necessitates defining robust and efficient methods for the in vitro expansion of antigen-specific T cells then infused into patients. To address this challenge, artificial antigen presenting cells (AAPCs) have been developed. They constitute a reliable and easily usable platform to stimulate and amplify antigen-specific CD4(+) T cells. Here, we review the recent advances in understanding the functions of CD4(+) T cells in immunity and in immune tolerance, and their use for ACT. We also describe the characteristics of different AAPC models and the way to improve their stimulating functions. Finally, we discuss the potential interest of these AAPCs, both as fundamental tools to decipher CD4(+) T cell responses and as reagents to generate clinical grade antigen-specific CD4(+) T cells for immunotherapy.
format Online
Article
Text
id pubmed-6533590
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65335902019-05-31 HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy Couture, Alexandre Garnier, Anthony Docagne, Fabian Boyer, Olivier Vivien, Denis Le-Mauff, Brigitte Latouche, Jean-Baptiste Toutirais, Olivier Front Immunol Immunology CD4(+) T cells differentiate into various T helper subsets characterized by distinct cytokine secreting profiles that confer them effector functions adapted to a variety of infectious or endogenous threats. Regulatory CD4(+) T cells are another specialized subset that plays a fundamental role in the maintenance of immune tolerance to self-antigens. Manipulating effector or regulatory CD4(+) T cells responses is a promising immunotherapy strategy for, respectively, chronical viral infections and cancer, or severe autoimmune diseases and transplantation. Adoptive cell therapy (ACT) is an emerging approach that necessitates defining robust and efficient methods for the in vitro expansion of antigen-specific T cells then infused into patients. To address this challenge, artificial antigen presenting cells (AAPCs) have been developed. They constitute a reliable and easily usable platform to stimulate and amplify antigen-specific CD4(+) T cells. Here, we review the recent advances in understanding the functions of CD4(+) T cells in immunity and in immune tolerance, and their use for ACT. We also describe the characteristics of different AAPC models and the way to improve their stimulating functions. Finally, we discuss the potential interest of these AAPCs, both as fundamental tools to decipher CD4(+) T cell responses and as reagents to generate clinical grade antigen-specific CD4(+) T cells for immunotherapy. Frontiers Media S.A. 2019-05-17 /pmc/articles/PMC6533590/ /pubmed/31156634 http://dx.doi.org/10.3389/fimmu.2019.01081 Text en Copyright © 2019 Couture, Garnier, Docagne, Boyer, Vivien, Le-Mauff, Latouche and Toutirais. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Couture, Alexandre
Garnier, Anthony
Docagne, Fabian
Boyer, Olivier
Vivien, Denis
Le-Mauff, Brigitte
Latouche, Jean-Baptiste
Toutirais, Olivier
HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy
title HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy
title_full HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy
title_fullStr HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy
title_full_unstemmed HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy
title_short HLA-Class II Artificial Antigen Presenting Cells in CD4(+) T Cell-Based Immunotherapy
title_sort hla-class ii artificial antigen presenting cells in cd4(+) t cell-based immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533590/
https://www.ncbi.nlm.nih.gov/pubmed/31156634
http://dx.doi.org/10.3389/fimmu.2019.01081
work_keys_str_mv AT couturealexandre hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy
AT garnieranthony hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy
AT docagnefabian hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy
AT boyerolivier hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy
AT viviendenis hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy
AT lemauffbrigitte hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy
AT latouchejeanbaptiste hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy
AT toutiraisolivier hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy